错配修复蛋白表达水平与肾细胞癌预后

Expression Level of DNA Mismatch Repair Protein in Renal Tissues and Clinical Prognosis of Renal Cancer

目的 研究错配修复基因hMLH1和hMSH2在不同肾组织中的表达水平及其对肾癌预后的预测。方法采用免疫组织化学方法检测71例肾癌组织及其癌周正常组织,31例肾良性病变组织石蜡标本中hMLH1、hMSH2的表达水平,同时收集所有标本的详细病理学资料,将蛋白表达水平与病理结果进行对比。结果 hMLH1和hMSH2的表达水平在肾良性病变中均明显高于癌组织和癌周正常组织,在高分化肾癌中均明显高于低分化肾癌,1年内无复发组显著高于1年内复发组;hMSH2在无转移组中的表达显著高于有转移组,而hMLH1在有无转移组的表达差异无显著性意义。结论 hMLH1、hMSH2两种修复蛋白在肾癌和肾良性病变组织中的表达水平有明显差异,且与肿瘤分化程度和肿瘤复发密切相关;hMSH2与肾癌转移有关,hMLH1与转移的关系不明显。hMSH2和hMLH1蛋白表达水平对肾癌预后有一定的预测作用。

Objective To study the expression level of hMSH2, hMLH1 and their relationship with cancer prognosis. Methods The protein levels of hMSH2 and hMLH1 were detected by using immunohis-tochemistry in 71 cases of renal cancer and 31 cases of benign renal tissues. Results hMSH2 and hMLH1 protein were more highly expressed in benign tissues than in cancer and cancer adjacent normal tissues. Comparison of different cancer grade, tumor invasion and tumor recurrence revealed that the expression levels of hMSH2 and hMLH1 were higher in low cancer grade and no recurrence than in high cancer grade or recurrence; The expression level of hMSH2 was higher in non-invasive tumors than in invasive tumors (P<0. 05). Conclusion The expression levels of hMSH2 and hMLH1 were significantly higher in benign tissues than in cancer tissues. There were different expression levels in different stages of renal cancers. hMSH2 was closely related with cancer transfer, while hMLH1 showed no relationship with cancer transfer. hMSH2 and hMLH1 are possible biomarkers of clinical prognosis in renal cancer grade, cancer invasive and cancer recurrence.